新PD-1/PD-L1阻害剤

製品コード 製品名 製品説明 文献中Selleckの製品使用例 お客様のフィードバック
A2013 Durvalumab Durvalumab is a selective, high affinity human IgG1 mAb that blocks programmed cell death ligand-1 (PD-L1) binding to PD-1 (IC50=0.1 nM) and CD80 (IC50=0.04 nM). MW=146.3 kDa.
A2016 Camrelizumab Camrelizumab is a humanized anti-PD-1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2 to PD-1 with immune checkpoint inhibitory and antineoplastic activities.
A2017 Spartalizumab Spartalizumab is a humanized anti-PD-1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2 to PD-1. It binds to PD-1 with high affinity and inhibits the biological activity of PD-1.
全てのPD-1/PD-L1阻害剤